Skip to main content

Best of 2022: EULAR 2022 Top 10 Abstracts

Editor's note: this article originally appeared June 10, 2022, and is being shared again as a Best of 2022. Enjoy!

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media…

Depression and RA DANBIO OP0067: Depression is a major risk factor (6X!) for mortality in RA.

EULAR 2022 Updated recommendations for the management of rheumatoid arthritis

Steroids in RA – the GLORIA GLORIA promotes Steroids!  Abstract #OP0263

Oral Surveillance (1133) Rehashed 

Buch MH, et al. POS0237  

Charles-Schoeman C, et al.

Karpouzas G, et al. POS0519

Giles JT, et al. POS0520

CAR-T Cell Therapy in SLE. Abstract OP0279 

ARIAA – Abatacept in Pre-Clinical RA Has persistent effects! Abstract #POS0531

EARLIER study OP0070

PMR and Sarilumab SAPHYR Study: Abstract  LB0006

Anti-malarials in combination with bDMARDs and tsDMARDs Abstract #POS0242

Topical Bicarbonate for Gouty Attacks?  Abstract OP0179 

Honorable Mention:

Serious infections causing serious flares of SLE  Infections Drive SLE Flares. Abstract OP0143

TYK2 inhibition in SLE  Deucravacitinib Succeeds in SLE Phase 2 study. Abstract LB0004 “PAISLEY” study

BE OPTIMAL – Bimekizumab  in bDMARD-naïve PsA.  Abstract LB0001

Bimekizumab BE COMPLETE trial. Abstract OP0255 


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has received compensation as an advisor or consultant on this subject